At 48, Jill Smokler, founder of Scary Mommy, was diagnosed with glioblastoma in May 2024, a stark reminder of cancer's relentless grip, even as another founder, Connor Christou, used an AI chatbot to navigate his own aggressive lymphoma diagnosis. Aggressive cancers continue to claim lives rapidly, but new AI tools are beginning to offer individuals unprecedented ways to engage with their complex medical data and treatment decisions. As AI becomes more sophisticated, a growing divide will likely emerge between patients who can leverage these tools for enhanced medical advocacy and those who cannot, potentially impacting outcomes and the patient-doctor dynamic.
The Aggression of Glioblastoma
- Jill Smokler received a glioblastoma diagnosis in May 2024, according to NBC 5 Dallas-Fort Worth. This aggressive brain cancer, as reported by KCRG, progresses rapidly and often proves fatal.
Glioblastoma's swift progression from diagnosis to death reveals the severe limitations of current treatment options. The disease leaves little time for patient-led interventions, underscoring the biological limits of medical technology.
A New Tool in the Fight: AI for Patient Advocacy
Connor Christou, a 35-year-old founder, received an aggressive, fast-growing non-Hodgkin’s lymphoma diagnosis. He utilized the AI chatbot Claude to analyze his medical data, including scan results and wearable output, to formulate better questions for his doctors, according to TechCrunch. This proactive use of AI marks a shift in patient empowerment, moving beyond simple information retrieval to active data analysis.
Navigating Complex Diagnoses
Christou gathered 12 medical opinions regarding his treatment; 11 recommended aggressive chemotherapy, TechCrunch reports. He used AI to critically evaluate these recommendations, enabling him to challenge the overwhelming expert consensus. AI's capacity to validate or challenge established medical advice transforms the patient's role in high-stakes treatment decisions.
The Future of AI in Healthcare
AI's true power for patients lies in its ability to synthesize complex personal medical data into actionable questions, enabling deeper engagement with care teams and challenging expert consensus. By Q3 2026, AI tools like Claude are projected to increasingly disrupt traditional medical consultation models, requiring healthcare systems to adapt to patients arriving with AI-generated analyses and questions.
